ASMB Stock Analysis: Buy, Sell, or Hold?
ASMB - Assembly Biosciences, Inc
$28.24
1.87 (7.09%)
▲
5d:
+2.62%
30d:
-16.31%
90d:
-9.05%
BUY
MODERATE Confidence
Last Updated: February 3, 2026
Earnings: Mar 19, 2026
Get Alerted When ASMB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ASMB shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ASMB shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ASMB is currently trading at $28.24, which is considered slightly low relative to its 30-day fair value range of $27.08 to $32.49.
Technical Outlook: Technically, ASMB is in a uptrend. The price is approaching resistance at $28.64. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.1% recently.
Market Sentiment: ASMB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $47.75 (+69.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ASMB is in a uptrend. The price is approaching resistance at $28.64. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.1% recently.
Market Sentiment: ASMB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $47.75 (+69.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$27.08 -
$32.49
Company Quality Score
50/100
(HOLD)
Options IV Signal
44th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
64.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 44th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.1%)
- BULLISH: Trading 69.1% below Wall St target ($47.75)
Fair Price Analysis
30-Day Fair Range
$27.08 -
$32.49
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$4.08
(14.4%)
Support & Resistance Levels
Support Level
$24.68
Resistance Level
$28.64
Current Trend
Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-8.06
Wall Street Target
$47.75
(+69.1%)
Revenue Growth (YoY)
57.6%
Profit Margin
-103.6%
Last updated: February 03, 2026 8:26 PM ET
Data refreshes hourly during market hours. Next update: 9:26 PM
Data refreshes hourly during market hours. Next update: 9:26 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ASMB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$477 | 55 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 51 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$514 | 61 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$91 | 61 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$847 | 53 HOLD |
